Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases.
Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases.
复制标题
DOI:
10.3892/ijmm.16.2.263
复制
发表时间:
2005-08
影响因子:
5.4
通讯作者:
Y. Kato;Y. Nagashima;Y. Baba;Toshiro Kawano;M. Furukawa;A. Kubota;S. Yanoma;Yukari Imagawa-Ishiguro;K. Satake;T. Taguchi;R. Hata;I. Mochimatsu;I. Aoki;Y. Kameda;Y. Inayama;M. Tsukuda
中科院分区:
文献类型:
--
作者:
Y. Kato;Y. Nagashima;Y. Baba;Toshiro Kawano;M. Furukawa;A. Kubota;S. Yanoma;Yukari Imagawa-Ishiguro;K. Satake;T. Taguchi;R. Hata;I. Mochimatsu;I. Aoki;Y. Kameda;Y. Inayama;M. Tsukuda
SPARC (secretory protein acidic and rich in cysteine), also known as osteonectin or BM-40, associates with progression in various kinds of tumors. We have examined whether SPARC expression can be a prognostic marker for patients with head and neck squamous cell carcinomas (HN-SCC). We examined immunolocalization of SPARC in 86 clinical specimens of tongue carcinoma. Although there was no correlation between SPARC positivity in the tumor cells and tumor stages, the 5-year overall survival rate was significantly lower in the SPARC positive cases (28.6%) than in the SPARC negative cases (91.7%), confined to stage II patients (p < 0.001, Wilcoxon test). Additionally, in stage II cases (n = 3), frequency of the postoperative metastasis was significantly higher in SPARC positive cases (5/8, 62.5%) than in the negative cases (1/15, 6.7%) (p < 0.01, chi2 test). Together with these results, SPARC can be a beneficial prognostic marker for the stage II tongue carcinoma, of which clinical outcomes are sometimes difficult to predict.